Navigation Links
ev3 Inc. Reports Third Quarter 2008 Financial Results
Date:10/31/2008

e entry of a new competitor and the ongoing physician trialing of competitive devices. However, we believe that physician trialing of competitive products ultimately will confirm the differentiated clinical performance and value that the SilverHawk Plaque Excision System offers as a front-line therapy in treating peripheral artery disease. In addition, interest in the SilverHawk is gathering momentum outside the U.S., and we believe that physician enthusiasm for our new DEFINITIVE clinical trial strategy could have a positive impact on sales and procedure adoption."

ev3's net loss for the third quarter of 2008 declined to $(7.3) million versus $(36.5) million in the third quarter of 2007 and $(27.4) million in the second quarter of 2008. ev3's net loss in the third quarter of 2007 reflected a special charge of $20.2 million and ev3's net loss in the second quarter of 2008 reflected a non-cash impairment charge of $10.5 million. ev3's net loss per common share was $(0.07) for the third quarter of 2008 versus a net loss per common share of $(0.60) in the third quarter of 2007 and a net loss per common share of $(0.26) in the second quarter of 2008. Total weighted average common shares outstanding used in the per common share calculations were 104.5 million and 60.4 million for the third quarter of 2008 and 2007, respectively, and 104.2 million for the second quarter of 2008. ev3's cash and cash equivalents balance was $45.9 million as of the end of the third quarter of 2008, an increase of $7.2 million compared to the end of the second quarter of 2008. This increase was primarily due to cash generated by operations during the third quarter of 2008.

ev3's non-GAAP adjusted net income was $3.9 million, or $0.04 per diluted share, for the third quarter of 2008. ev3's guidance range for non-GAAP adjusted EPS was $(0.02) to $0.01 per diluted share. ev3's non-GAAP adjusted net income and adjusted net earnings per share exclude amortization expense of $8.1 mill
'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. eResearchTechnology Reports Third Quarter 2008 Results
2. Thoratec Reports 44 Percent Increase in Third Quarter Revenues
3. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
4. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... October 18, 2014 The Asia-Pacific Liquid ... segments the concerned market in Asia-Pacific with analysis and ... million in 2013, and is expected to reach $380.0 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. This also provides ...
(Date:10/18/2014)... October 18, 2014 According to a ... & Well Type - Global Trends & Forecasts up ... $31 billion in 2011. This value is expected to ... by 2017, with 10% CAGR during the same period. ... fracturing production market in terms of hydraulic horse power ...
(Date:10/17/2014)... have received a $451,781 Air Force Office of Scientific ... micro- and nano-scale level that will provide clues for ... Mechanical and Aerospace Engineering, said the new technology and ... X-rays of an aircraft,s wing., "We,ll be able to ... look at it on this scale," Huang said. "Certain ...
(Date:10/17/2014)... DE (PRWEB) October 17, 2014 ... among top employers, as published in today’s print ... Science Careers’ annual Top Employers Survey polled employees ... determine the 20 best employers. Rankings were ... were asked to rate their companies on 23 ...
Breaking Biology Technology:The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4UT Arlington project to detect possible damages in aircraft parts early in process 2DuPont Named Top Employer by Science Magazine 2DuPont Named Top Employer by Science Magazine 3
... BASEL, Switzerland, Dec. 5 Roche (SWX:,ROG.VX; RO.S) announced ... (Nasdaq: VMSI ), as required by Ventana,s bylaws, ... of directors at,Ventana,s 2008 annual stockholders meeting., On ... acquire all of the,outstanding common shares of Ventana for ...
... Cost, Savings and Avoidance of Approximately $1.5 Billion by 2010 and Incur, Associated ... ... 11% Increase in Indicative Dividend for 2008 and Declares ... Quarterly Dividend, * Revises 2007 Full-Year GAAP EPS Guidance to ...
... January for lead antibody program ... ... Inc. (TSX:,ARI), a biotechnology company discovering and developing the next wave of,antibody ... transfer agreement for its CD44 Cancer,Stem Cell antibody with Avid Bioservices, a ...
Cached Biology Technology:Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 2Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 3Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 4Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 5Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 6Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 7Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 8Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 2Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 3Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 4Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 5Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 6Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 7Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 8Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 9Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 10Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 11ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody 2ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody 3
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... new synthesis of recent research findings to inform their ... two states. , The Ecology and Management of ... Synthesis of the Relevant Biophysical Science and Implications for ... the U.S. Forest Service,s Pacific Northwest Research Station, is ... a synthesis of the large body of scientific information ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... 16, 2013) A team of American and Chinese conservationists ... counted nearly 1,000 wild yaks from a remote area of ... this species, which was decimated by overhunting in the mid ... rugged area called Hoh Xil a national nature reserve ...
... 2013 Elsevier, a world-leading provider of scientific, technical ... announce the launch of a new journal, Journal ... ). JUOGR is to publish ... practices in the area of evaluation, development and management ...
... $14 million from the William & Nancy Thompson Family ... County, UC Irvine is helping lead the charge against ... in the U.S. autism., The funding created the ... which will provide unparalleled access to assessment, diagnosis, care ...
Cached Biology News:Yaks are back 2UCI research turns the corner on autism 2UCI research turns the corner on autism 3